Our philosophy is to comprehensively understand a molecule’s mechanisms of action and risk profile, as early as possible in the drug development process, to minimise the chance of unanticipated issues arising in the clinical phases.
To accomplish this, we create in vitro models that mimic disease biology as closely as possible, to allow therapeutic candidates to be tested in a context that yields meaningful data and from which decisions can be reliably taken. Our models are designed to yield information more reflective of the true MoAs and can highlight potential safety concerns early. Our approach to enhanced in vitro characterisation is in alignment with initiatives to reduce the burden of in vivo testing requirements and is therefore safer and more cost-effective.
Drawing on our immuno-oncology expertise, we have built up an array of assay systems to recreate immune cell interactions in the tumour microenvironment, intended to be as faithful to the physiological processes they are emulating as possible. With a strong focus on novel and emerging therapeutic classes that are designed to modulate these processes, our assay platforms are applicable to oncology, auto-immunity and beyond.
Explore our interactive tumour microenvironment diagram to learn more about the in vitro models and co-culture formats we can apply to interrogate the effect of your drug on various immune cell types and their interplay with target cells. Each of these models can be harnessed and readily adapted to suit the in vitro testing of your drug candidates. Contact us to discuss your immunology requirements.
To bolster the data produced from our in vitro platforms, we can facilitate ex vivo assessments in the most physiologically relevant setting - using primary tissues from patients. We can perform custom phenotypic and functional assessments to validate the conclusions drawn from in vitro models.
Book a meeting with one of our translational immunologists to discuss how we can apply our in vitro models or ex vivo tissue assessments to accelerate your drug discovery programs.